| DIRECT COMPETITOR COMPARISON | |
| APPA | ALKS | DEPO | DRRX | Industry | | Market Cap: | 37.01M | 817.82M | 168.00M | 202.12M | 128.60M | | Employees: | 32 | 570 | 81 | 171 | 181 | | Qtrly Rev Growth (yoy): | 1,645.30% | 1.80% | 63.10% | 26.30% | 14.60% | | Revenue (ttm): | 1.16M | 295.19M | 53.21M | 27.14M | 31.21M | | Gross Margin (ttm): | 100.00% | 84.83% | 17.88% | -93.39% | 72.39% | | EBITDA (ttm): | -11.60M | 116.61M | -28.72M | -38.00M | -1.65M | | Oper Margins (ttm): | -1,032.16% | 32.44% | -55.94% | -149.71% | 2.37% | | Net Income (ttm): | -11.98M | 80.25M | -29.63M | -40.05M | N/A | | EPS (ttm): | -0.389 | 0.842 | -0.578 | -0.487 | N/A | | P/E (ttm): | N/A | 10.25 | N/A | N/A | 13.73 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 2.18 | | P/S (ttm): | 31.57 | 2.86 | 3.27 | 7.48 | 3.28 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | ALKS | | 4 Platform Drugmakers to Invest In
Tue, Nov 24 -
at Motley Fool | | • | DEPO | | Depomed to Present at Piper Jaffray's 21st Annual Health Care Conference
Tue, Nov 24 -
Business Wire | | • | DRRX | | DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
Mon, Nov 23 -
PR Newswire | | • | ALKS | | [$$] The Ascending Trend Line Breaks
Fri, Nov 20 -
at RealMoney by TheStreet.com | | • | ALKS | | Should You Buy It? Alkermes
Thu, Nov 19 -
RealMoney by TheStreet.com | | • | ALKS | | Good News for Alkermes' Pipeline
Wed, Nov 18 -
Zacks.com | | • | DEPO | | Depomed Promotes William Callahan to Vice President of Operations
Wed, Nov 18 -
Business Wire | | • | ALKS | | Tuesday's Big Gainers on Heavy Volume
Wed, Nov 18 -
at Seeking Alpha | | • | ALKS | | [$$] Activity Jumps in Biotech and Drug Firms
Tue, Nov 17 -
at The Wall Street Journal Online | | • | ALKS | | Alkermes Begins Trials for ALKS 33
Tue, Nov 17 -
at Fox Business | | • | DEPO | | Santarus, Depomed Poised to Gain from Anticipated Sales of Glumetza
Mon, Nov 16 -
at Seeking Alpha | | • | DEPO | | Depomed Ranked #13 on Deloitte's Technology Fast 500TM
Mon, Nov 16 -
Business Wire | | • | DEPO | | DEPOMED INC Financials
Fri, Nov 13 -
EDGAR Online Financials | | • | DEPO | | DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Tue, Nov 10 -
EDGAR Online | | • | DRRX | | DURECT CORP Financials
Fri, Nov 6 -
EDGAR Online Financials | | • | DRRX | | DURECT CORP Files SEC form 10-Q, Quarterly Report
Mon, Nov 2 -
EDGAR Online | | • | DRRX | | DURECT Corporation Earnings Call scheduled for 4:30 pm ET today
Thu, Oct 29 -
CCBN | | • | DRRX | | DURECT CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Thu, Oct 29 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
0.01 (1.08%) 
Competitors
